Exploring occupancy of the histamine H 3 receptor by pitolisant in humans using PET

التفاصيل البيبلوغرافية
العنوان: Exploring occupancy of the histamine H 3 receptor by pitolisant in humans using PET
المؤلفون: Thierry Duvauchelle, Philippe Robert, Pablo Rusjan, Pamela Sabioni, Isabelle Boileau, Patricia Di Ciano, Bernard Le Foll, Marc Capet, Jean-Charles Schwartz, Esmaeil Mansouri, Alexia Laveillé
المصدر: British Journal of Pharmacology. 177:3464-3472
بيانات النشر: Wiley, 2020.
سنة النشر: 2020
مصطلحات موضوعية: 0301 basic medicine, Pharmacology, Pitolisant, business.industry, Antagonist, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, Radioligand, Inverse agonist, Medicine, Histamine H3 receptor, Receptor, business, H3 receptor antagonist, 030217 neurology & neurosurgery, Histamine
الوصف: Background and purpose BF2.649 (pitolisant, Wakix®) is a novel histamine H3 receptor inverse agonist/antagonist recently approved for the treatment of narcolepsy disorder. The objective of the study was to investigate in vivo occupancy of H3 receptors by BF2.649 using PET brain imaging with the H3 receptor antagonist radioligand [11 C]GSK189254. Experimental approach Six healthy adult participants were scanned with [11 C]GSK189254. Participants underwent a total of two PET scans on separate days, 3 h after oral administration of placebo or after pitolisant hydrochloride (40 mg). [11 C]GSK189254 regional total distribution volumes were estimated in nine brain regions of interest with the two tissue-compartment model with arterial input function using a common VND across the regions. Brain receptor occupancies were calculated with the Lassen plot. Key results Pitolisant, at the dose administered, provided high (84 ± 7%; mean ± SD) occupancy of H3 receptors. The drug was well-tolerated, and participants experienced few adverse events. Conclusion and implications The administration of pitolisant (40 mg) produces a high occupancy of H3 receptors and may be a new tool for the treatment of a variety of CNS disorders that are associated with mechanisms involving H3 receptors.
تدمد: 1476-5381
0007-1188
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::505492d54cee86108180eb81f9e387c0Test
https://doi.org/10.1111/bph.15067Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........505492d54cee86108180eb81f9e387c0
قاعدة البيانات: OpenAIRE